Latifat Abdulsalam

Ms. Latifat Abdulsalam

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2025 in Polymers
Verified
Journal Article
Open access
PDF file
LALatifat Abdulsalam
Latifat Abdulsalam
SASadam Abubakar
Sadam Abubakar
IPIkfa Permatasari
Ikfa Permatasari
Anas Abdulwahab LawalAnas Abdulwahab Lawal
Anas Abdulwahab Lawal
SHIHAB UDDINSHIHAB UDDIN
SHIHAB UDDIN
Irshad AhmadIrshad Ahmad
Irshad Ahmad
The growing dependence on plastics is driving a sharp increase in environmental pollution, posing serious risks to human health. This issue necessitates immediate attention and proactive measures to mitigate its impact on both individuals and the broader ecosystem. From this viewpoint, biocompatible and biodegradable polymers, both synthetic and natural, have emerged as vital materials for applications in biomedicine, packaging, and environmental sustainability. The main advantages of biodegradable polymer materials lie in conserving fossil fuel resources, utilizing inedible biomass, and enabling environmentally friendly production processes. In this context, this review thoroughly discusses the categorization of biocompatible and biodegradable polymers into natural and synthetic types, detailing their structural characteristics, mechanisms of biodegradation, and compatibility matrices appropriate for biomedical, environmental, and industrial uses. It also addresses recent advancements in polymer synthesis technology, highlighting significant progress in polymer functionalization, responsiveness to stimuli, and environmentally friendly biobased synthesis methods. Additionally, it identifies challenges such as mechanical constraints, control over degradation, and expense, while also discussing future opportunities in the field of polymer science.

20 December 2024 in Nanomedicine
Verified
Journal Article
Closed access
LALatifat Abdulsalam
Latifat Abdulsalam
JMJames Mordecai
James Mordecai
Irshad AhmadIrshad Ahmad
Irshad Ahmad

Verified
Journal Article
Open access
PDF file
SASadam Abubakar
Sadam Abubakar
LALatifat Abdulsalam
Latifat Abdulsalam
LFLamin Fatty
Lamin Fatty
RKRimsha Kanwal
Rimsha Kanwal
Muhammad NaeemMuhammad Naeem
Muhammad Naeem
Irshad AhmadIrshad Ahmad
Irshad Ahmad
Cancer immunotherapy has recently become an essential approach for treating cancer, showing considerable promise as a substitute for surgery, radiation therapy, and conventional chemotherapy. It primarily aims to boost the host’s natural defense system to combat cancer malignancies by utilizing components of immune checkpoint blockades (ICBs), mainly programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), along with elements of adoptive cellular therapies (ACTs) like Chimeric Antigen Receptor (CAR) therapy, T Cell Receptor (TCR) therapy and Tumor-Infiltrating Lymphocyte (TIL) therapy. However, cancer cells tend to undermine the effectiveness of cancer immunotherapeutic strategies by employing one or more immune evasion mechanisms. This review briefly highlights how key mechanisms of cancer immune evasion confer resistance to immunotherapy and how the Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (CRISPR)/Cas9 systems, as gene-editing tools, are poised to enhance cancer immunotherapy for treating challenging cancers. We emphasize that (CRISPR/Cas9) systems can be used to explore and positively alter the genes of the immune system, boosting the effectiveness of cancer immunotherapy by editing immune checkpoints, TILs, and CAR-T cells, and disrupting genes, facilitating tumors’ evasion of the immune system. Furthermore, we highlight the growing interest in emerging base editor technology to engineer natural killer (NK) cells to overcome NK-cell-based immunotherapy challenges, particularly human leukocyte antigens (HLA)-mediated limitations, and to engineer CAR-T cells for improved immunotherapy outcomes.

30 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
LALatifat Abdulsalam
Latifat Abdulsalam
SASadam Abubakar
Sadam Abubakar
IPIkfa Permatasari
Ikfa Permatasari
Anas Abdulwahab LawalAnas Abdulwahab Lawal
Anas Abdulwahab Lawal
SHIHAB UDDINSHIHAB UDDIN
SHIHAB UDDIN
Irshad AhmadIrshad Ahmad
Irshad Ahmad
The growing dependence on plastics is driving a sharp increase in environmental pollution, posing serious risks to human health. This issue necessitates immediate attention and proactive measures to mitigate its impact on both individuals and the broader ecosystem. From this viewpoint, Biocompatible and biodegradable polymers, both synthetic and natural, have emerged as vital materials for applications in biomedicine, packaging, and environmental sustainability. The main advantages of biodegradable polymer materials lie in conserving fossil fuel resources, utilizing inedible biomass, and enabling environmentally friendly production processes. In this context, this review thoroughly discusses the categorization of biocompatible and biodegradable polymers into natural and synthetic types, detailing their structural characteristics, mechanisms of biodegradation, and compatibility matrices appropriate for biomedical, environmental, and industrial uses. It also addresses recent advancements in polymer synthesis technology, highlighting significant progress in polymer functionalization, responsiveness to stimuli, and environmentally friendly biobased synthesis methods. Additionally, it identifies challenges such as mechanical constraints, control over degradation, and expense, while also discussing future opportunities in the field of polymer science.

18 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SASadam Abubakar
Sadam Abubakar
LALatifat Abdulsalam
Latifat Abdulsalam
LFLamin Fatty
Lamin Fatty
RKRimsha Kanwal
Rimsha Kanwal
Muhammad NaeemMuhammad Naeem
Muhammad Naeem
Irshad AhmadIrshad Ahmad
Irshad Ahmad
Cancer immunotherapy has recently become an essential approach for treating cancer, showing considerable promise as a substitute for surgery, radiation therapy, and conventional chemotherapy. It primarily aims to boost the host’s natural defense system to com-bat cancer malignancies by utilizing components of immune checkpoint blockades (ICBs), mainly programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and along with elements of adoptive cellular therapies (ACTs) like Chimeric Antigen Receptor (CAR) therapy, T Cell Receptor (TCR) therapy and Tu-mor-Infiltrating Lymphocyte (TIL) therapy. However, cancer cells tend to undermine the effectiveness of cancer immunotherapeutic strategies by employing one or more immune evasion mechanisms. The present review briefly discusses the key mechanisms of cancer immune evasion and highlights how the CRISPR/Cas9 systems, as gene editing tools, are set to enhance cancer immunotherapy for treating various challenging cancers. We emphasize that CRISPR/Cas9 systems can be used to explore and positively alter the genes of the immune system, boosting the effectiveness of cancer immunotherapy by editing immune checkpoints, TILs, and CAR-T cells, and disrupting genes facilitating tumors to evade the immune system.